14.38
price down icon2.38%   -0.35
after-market Handel nachbörslich: 14.38
loading
Schlusskurs vom Vortag:
$14.73
Offen:
$14.58
24-Stunden-Volumen:
1.42M
Relative Volume:
0.88
Marktkapitalisierung:
$2.48B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
79.89
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-3.23%
1M Leistung:
-14.35%
6M Leistung:
-2.57%
1J Leistung:
-14.51%
1-Tages-Spanne:
Value
$14.17
$14.74
1-Wochen-Bereich:
Value
$14.17
$15.18
52-Wochen-Spanne:
Value
$13.40
$20.68

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Firmenname
Acadia Pharmaceuticals Inc
Name
Telefon
858-558-2871
Name
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Name
Mitarbeiter
654
Name
Twitter
@acadiapharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
14.38 2.48B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Eingeleitet Deutsche Bank Hold
2025-01-03 Herabstufung Guggenheim Buy → Neutral
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-03-12 Herabstufung Mizuho Buy → Neutral
2024-03-12 Bestätigt Needham Buy
2024-01-30 Eingeleitet Robert W. Baird Outperform
2024-01-24 Hochstufung Needham Hold → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-12-14 Herabstufung Deutsche Bank Buy → Hold
2023-12-13 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-06 Hochstufung Mizuho Neutral → Buy
2023-10-17 Eingeleitet UBS Buy
2023-10-10 Hochstufung JP Morgan Neutral → Overweight
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-04 Herabstufung Goldman Neutral → Sell
2022-11-01 Eingeleitet Loop Capital Hold
2022-08-08 Herabstufung Citigroup Buy → Neutral
2022-08-05 Herabstufung Citigroup Buy → Neutral
2022-06-21 Herabstufung Jefferies Buy → Underperform
2022-06-16 Hochstufung Jefferies Hold → Buy
2022-03-16 Hochstufung Canaccord Genuity Hold → Buy
2022-02-09 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-05 Hochstufung Citigroup Neutral → Buy
2021-12-21 Herabstufung Guggenheim Buy → Neutral
2021-11-01 Hochstufung Guggenheim Neutral → Buy
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-06-10 Eingeleitet Berenberg Hold
2021-04-07 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-06 Herabstufung Canaccord Genuity Buy → Hold
2021-04-06 Herabstufung Goldman Buy → Neutral
2021-04-06 Herabstufung Jefferies Buy → Hold
2021-04-06 Herabstufung Mizuho Buy → Neutral
2021-04-05 Herabstufung Raymond James Outperform → Mkt Perform
2021-03-10 Herabstufung BofA Securities Buy → Neutral
2021-03-09 Herabstufung Citigroup Buy → Neutral
2021-03-09 Herabstufung Guggenheim Buy → Neutral
2021-03-09 Bestätigt H.C. Wainwright Buy
2021-03-09 Herabstufung Raymond James Strong Buy → Outperform
2021-03-09 Herabstufung Stifel Buy → Hold
2020-12-16 Eingeleitet Mizuho Buy
2020-11-16 Hochstufung Raymond James Outperform → Strong Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Eingeleitet Morgan Stanley Overweight
2020-07-07 Hochstufung Stifel Hold → Buy
2020-04-16 Eingeleitet Jefferies Buy
2020-03-31 Hochstufung Goldman Neutral → Buy
2020-03-06 Eingeleitet Citigroup Buy
2019-12-16 Eingeleitet Guggenheim Buy
2019-10-24 Eingeleitet Oppenheimer Perform
2019-10-01 Eingeleitet RBC Capital Mkts Outperform
2019-09-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-10 Hochstufung Canaccord Genuity Hold → Buy
2019-07-23 Bestätigt Needham Buy
2018-12-10 Eingeleitet Canaccord Genuity Hold
2018-09-21 Hochstufung Piper Jaffray Neutral → Overweight
2018-08-09 Bestätigt Stifel Hold
2018-08-07 Eingeleitet Stifel Hold
2018-08-06 Herabstufung Piper Jaffray Overweight → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

pulisher
Apr 20, 2025

Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus

Apr 20, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 15, 2025

Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 15, 2025
pulisher
Apr 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance

Apr 13, 2025
pulisher
Apr 12, 2025

Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Apr 12, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 11, 2025
pulisher
Apr 11, 2025

Neuroscience Leader Acadia Expands Team with Major Equity Compensation Package - Stock Titan

Apr 11, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia

Apr 09, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView

Apr 08, 2025
pulisher
Apr 08, 2025

Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st

Apr 08, 2025
pulisher
Mar 31, 2025

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 31, 2025
pulisher
Mar 31, 2025

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR

Mar 25, 2025
pulisher
Mar 24, 2025

Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR

Mar 24, 2025
pulisher
Mar 20, 2025

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire

Mar 20, 2025
pulisher
Mar 18, 2025

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire

Mar 18, 2025
pulisher
Mar 17, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire

Mar 16, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Parkinson's Disease Therapeutics Market is expected to reach - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com

Mar 11, 2025
pulisher
Mar 10, 2025

Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News

Mar 10, 2025
pulisher
Mar 10, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 09, 2025

Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times

Mar 09, 2025

Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):